Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shilpa Medicare Limited ( (IN:SHILPAMED) ) has shared an update.
Shilpa Medicare Limited has received initial authorization from the European Medicine Agency for its Rivaroxaban Orodispersible Films, a generic version of Bayer AG’s Xarelto®. This product, designed for patient comfort, especially in geriatric patients, is bioequivalent to the reference product and is used to treat and prevent various thrombotic conditions. The approval strengthens Shilpa’s position in the European market, where the oral Rivaroxaban formulations market is valued at approximately USD 2.5 billion, and marks the third approval for a prescription oral mouth dissolving film product from their Bengaluru facility.
More about Shilpa Medicare Limited
Shilpa Medicare Limited is a pharmaceutical company based in Raichur, Karnataka, India. The company specializes in manufacturing specialized finished dosage forms, including oral dispersible/dissolving films and transdermal patches. Their operations are supported by a facility in Bengaluru, Karnataka, which is approved by regulatory bodies such as the USFDA, Europe, and MHRA UK.
Average Trading Volume: 5,215
Technical Sentiment Signal: Buy
Current Market Cap: 80.77B INR
Find detailed analytics on SHILPAMED stock on TipRanks’ Stock Analysis page.